Challenges in maintaining medicine quality while aiming for universal health coverage
A qualitative analysis from Indonesia
Bibliographic Data
| ID | 21878816 |
|---|---|
| Authors | Amalia Hasnida (0000-0002-9264-334X, Erasmus University Rotterdam, corresponding author), Maarten Olivier Kok (0000-0001-8957-1253, Vrije Universiteit Amsterdam), Elizabeth Pisani (0000-0002-3674-631X, King's College London) |
| Year | 2021 |
| Volume | 6 |
| Issue | Suppl 3 |
| Pages | e003663 |
| Publication date | 2021-05-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | BMJ Global Health (JOURNAL) |
| Journal identifiers | ISSN: 2059-7908 • E-ISSN: 2059-7908 |
| Publisher | BMJ (PUBLISHER • GB) |
| DOI | 10.1136/bmjgh-2020-003663 |
| PMID | 34049935 |
| OpenAlex | W3165442713 |
| Language | EN |
| Citations received | 10 |
| References cited | 28 |
INTRODUCTION: Indonesia, the world's fourth most populous nation, is close to achieving universal health coverage (UHC). A widely-publicised falsified vaccine case in 2016, coupled with a significant financial deficit in the national insurance system, has contributed to concern that the rapid scale-up of UHC might undermine medicine quality. We investigated the political and economic factors that drive production and trade of poor-quality medicines in Indonesia. METHODS: We reviewed academic publications, government regulations, technical agency documents and news reports to develop a semi-structured questionnaire. We interviewed healthcare providers, policy-makers, medicine regulators, pharmaceutical manufacturers, patients and academics (n=31). We included those with in-depth knowledge about the falsified vaccine case or the pharmaceutical business, medicine regulation, prescribing practice and the implementation of UHC. We coded data using NVivo software and analysed by constant comparative method. RESULTS: The scale-up of UHC has cut revenues for physicians and pharmaceutical manufacturers. In the vaccine case, free, quality-assured vaccines were available but some physicians, seeking extra revenue, promoted expensive alternatives. Taking advantage of poor governance in private hospitals, they purchased cut-price 'vaccines' from freelance salespeople.A single-winner public procurement system which does not explicitly consider quality has slashed the price paid for covered medicines. Trade, industrial and religious policies simultaneously increased production costs, pressuring profit margins for manufacturers and distributors. They reacted by cutting costs (potentially threatening quality) or by market withdrawal (leading to shortages which provide a market for falsifiers). Shortages and physician-promoted irrational demand push patients to buy medicines in unregulated channels, increasing exposure to falsified medicines. CONCLUSION: Market factors, including political pressure to reduce medicine prices and healthcare provider incentives, can drive markets for substandard and falsified medicines. To protect progress towards UHC, policy-makers must consider the potential impact on medicine quality when formulating rules governing health financing, procurement, taxation and industry
Business · Environmental health · Political science · Public health · Qualitative research · Social science · Sociology · Healthcare Systems and Reforms · Medicine · Nursing · Pharmaceutical Economics and Policy · Pharmaceutical Quality and Counterfeiting
The challenges associated with the prevention of smuggling and counterfeiting health goods in Iran
Are quality medicines affordable? Evidence from a large survey of medicine price and quality in Indonesia
Uncertainties about the quality of medical products globally
Why falsified medicines reach patients
A study of the quality of cardiovascular and diabetes medicines in Malang District, Indonesia, using exposure-based sampling
How conflicts of interest hinder effective regulation of healthcare
Local systems, local solutions
A randomised survey of the quality of antibiotics and other essential medicines in Indonesia, with volume-adjusted estimates of the prevalence of substandard medicines
Managing medicines in decentralization
The availability of essential medicines in public healthcare facilities in Afghanistan
| Citations per year | 2.5 |
|---|---|
| Citation span | 2022 - 2026 (5) |
| Highly cited | No |